Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix Efficacy in Healthy Chinese Females
NCT00779766Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2008
- Primary completion
- Sep 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection, sponsored by GSK. Started Oct 2008; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00779766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00779766.